QuickView: An eye on commercialisation
Ocata has completed enrolment and published encouraging results in its Phase I/II trial of stem cell therapy in both dry age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD). It is pursuing the quicker orphan drug approval process of SMD and the large potential market of AMD by beginning an AMD Phase II trial and a pivotal trial in SMD. It has also secured a licensing agreement to use induced pluripotent stem cells (iPSC) as a platform for differentiating ocular tissue for other diseases. In spite of this recent clinical momentum, a weak capital position will require additional funding to reach clinical approval.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.